Journal article

Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018

Paulina Koszalka, Danielle Tilmanis, Merryn Roe, Dhanasekaran Vijaykrishna, Aeron C Hurt

ANTIVIRAL RESEARCH | ELSEVIER SCIENCE BV | Published : 2019

Abstract

Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to monitor for susceptibility post-BXM use, a cell culture-based focus reduction assay was developed to determine the susceptibility of 286 circulating seasonal influenza viruses, A(H1N1)pdm09, A(H3N2), B (Yamagata/Victoria) lineage viruses, including neuraminidase inhibitor (NAI) resistant viruses, to Baloxavir Acid (BXA), the active metabolic form of BXM. BXA was effective against all influenza subtypes tested with mean EC50 values (minimum-m..

View full abstract

Grants

Awarded by National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, USA


Funding Acknowledgements

The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.DV is supported by contract HHSN272201400006C from the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, USA.